Leaflet MACUGEN 0.3mg INJECTIBLE SOLUTION solution for injection
Indicated for: macular degeneration; diabetic macular edema
Route of administration: injectable
Substance: pegaptanib sodium (anti-VEGF aptamer)
ATC: S01LA03 (Sensory organs | Ocular vascular disorder agents | Antineovascularisation agents)
This medicine may cause vision disturbances.
Pegaptanib sodium is a medication used in the treatment of neovascular age-related macular degeneration (AMD). It works by inhibiting vascular endothelial growth factor (VEGF), reducing the formation of abnormal blood vessels in the retina.
The medication is administered via intravitreal injection, as directed by a doctor, usually once every six weeks. It is important for patients to attend scheduled treatments and inform the doctor of any unusual symptoms.
Patients should be aware of potential side effects, such as eye pain, inflammation, or infections. It is important to inform the doctor of any unusual symptoms.
Common side effects include eye pain, inflammation, and a foreign body sensation in the eye. In rare cases, severe reactions such as endophthalmitis or retinal detachment may occur. Patients should be informed of these risks before use.
General data about MACUGEN 0.3mg INJECTIBLE SOLUTION
- Substance: pegaptanib sodium
- Date of latest medicines list: 01-07-2013
- Product code: W43716001
- Concentration: 0.3mg
- Pharmaceutical form: solution for injection
- Quantity: 1
- Product type: Original
- Prescription status: S - Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.